Onconova Announced First Patient Dosed in Investigator-Initiated Phase II Study of Rigosertib in Recessive Dystrophic Epidermolysis Bullosa-Associated Squamous Cell Carcinoma

Onconova Therapeutics, Inc., announced that the first patient has been dosed in an investigator-initiated Phase II study to assess the efficacy and safety of rigosertib in patients with recessive dystrophic epidermolysis bullosa-associated locally advanced/metastatic squamous cell carcinoma.